Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route

Drug Delivery

Volumn 23, Issue 1, 2016, Pages 130-139

  Mittal, Deepti ^a   Md, Shadab ^a   Hasan, Quamrul ^a   Fazil, Mohammad ^a   Ali, Asgar ^a   Baboota, Sanjula ^a   Ali, Javed ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Bioavailability; brain disease; nanoparticles; Parkinson disease; rasagiline

Indexed keywords

CHITOSAN NANOPARTICLE; GLUTAMIC ACID; POLYMER; RASAGILINE; CHITOSAN; INDAN DERIVATIVE; NANOPARTICLE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUTION; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PHARMACOLOGICAL PARAMETERS; POLYDISPERSITY INDEX; PRIORITY JOURNAL; STEADY STATE; THERMOGRAPHY; TIGHT JUNCTION; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; BIOAVAILABILITY; CHEMISTRY; GOAT; INTRANASAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; NOSE MUCOSA; PARKINSON DISEASE; TISSUE DISTRIBUTION;

ADMINISTRATION, INTRANASAL; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; GOATS; INDANS; MALE; MICE; NANOPARTICLES; NASAL MUCOSA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TISSUE DISTRIBUTION;

EID: 84954311466     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.907372     Document Type: Article

References (32)

1. Artursson P, Lindmark T. (1994). Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 11: 1358-61.
2. Aydin RST, Pulat M. (2012). 5-Fluorouracil encapsulated chitosan nanoparticles for ph-stimulated drug delivery: evaluation of controlled release kinetics. J Nanomater 12:144-56.
3. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. (1997). Novel Hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 63:125-32.
4. Chenite A, Gori S, Shive M, et al. (2006). Monolithic gelation of chitosan solutions via enzymatic hydrolysis of urea. Carbo Polym 64: 419-24.
5. Chopra S, Patil GV, Motwani SK. (2007). Release modulating hydrophilic matrix systems of losartan potassium: Optimization of formulation using statistical experimental design. Eur J Pharm Biopharm 66:73-82.
6. Dash S, Murthy PN, Nath L, Chowdhury P. (2010). Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm 67:217-23.
7. Davis SS. (1997). Biomedical applications of nanotechnology-implications for drug targeting and gene therapy. Trends Biotechnol 15: 217-24.
8. Dhuria SV, Hanson LR, Frey WH. (2010). Intranasal delivery to the central nervous system: mechanism and experimental consideration. J Pharm Sci 99:1654-73.
9. Dyer AM, Hinchcliff M. (2002). Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan NPs. Pharm Res 19:998-1008.
10. Fan W, Yan W, Xu Z, Ni H. (2012). Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B: Biointer 90:21-7.
11. Fernández M, Negro S, Slowing K, et al. (2011). An effective novel delivery strategy of RAS for Parkinson's disease. Int J Pharm 419: 271-80.
12. Gallagher DA, Schrag A. (2008). Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 22:563-86.
13. Gavini E, Rassu G, Ferraro L, et al. (2011). Influence of glutamate on the in vivo intranasal absorption of rokitamycin from microspheres. J Pharm Sci 100:1488-502.
14. Genta I, Perugini P, Modena T, et al. (2003). Myconazole-loaded 6-oxychitin-chitosan microcapsules. Carbo Polym 52:11-18.
15. Haque S, Shadab M, Fazil M, et al. (2012). Venlafaxine loaded chitosan NPs for brain targeting, Pharmacokinetic and pharmacodynamic evaluation. Carbo Polym 89:72-9.
16. Illum L. (2000). Transport of drugs from the nasal cavity to central nervous system. Eur J Pharm Sci 11:1-18.
17. Joshi SA, Chavhan SS, Sawant KK. (2010). Rivastigmine-loaded PLGA and PBCA NPs: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 76: 189-99.
18. Kumar M, Misra A, Babbar AK, et al. (2008). Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 358:285-91.
19. Lakshmi MV, Rao S, Rao AL. (2010). Development and validation of RP-HPLC method for the estimation of RAS tablet dosage forms. Rasayan J Chem 3:621-4.
20. Md S, Khan RA, Mustafa G, et al. (2013). Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, Pharmacokinetic and Scintigraphy study in mice model. Eur J Pharm Sci 48:393-405.
21. Mittal D, Ali A, Md S, et al. (2013). Insights in to direct nose to brain delivery: current status and future perspective. Drug Deliv 21: 75-86.
22. Mustafa G, Baboota S, Ali J, Ahuja A. (2012). Formulation development of chitosan coated intranasal ropinirole nanoemulsion for better management option of Parkinson: an in vitro-ex vivo evaluation. Curr Nanosci 8:348-60.
23. Nussbaum RL, Ellis C. (2003). Alzheimer's disease and Parkinson's disease. N Engl Med 348:1356-64.
24. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Arch Neurol 62:241-8.
25. Pires A, Fortuna A, Alves G, Falcao A. (2009). Intranasal drug delivery: how, why and what for. J Pharm Sci 12:288-311.
26. Ravi PR, Aditya N, Patil S, Cherian L. (2013). Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization. Drug Deliv 51:1-7.
27. Schapira AHV. (2005). Present and future drug treatment for Parkinson's disease. J Neurol Neurosurg Psychiatr 76:1472-8.
28. Sofia P, Dimitrios B, Konstantinos A, et al. (2008). Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbo Polym 73:44-54.
29. Taylor JP, Hardy J, Fischbeck KH. (2002). Toxic proteins in neurodegenerative disease. Science 296:1991-5.
30. Wang X, Chi N, Tang X. (2008). Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm and Biopharm 70:735-40.
31. Wen Z, Yan Z, Hu K, et al. (2011). Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J Control Release 151:131-8.
32. Zhang Q, Jiang X, Jiang W, et al. (2004). Preparation of nimodipine loaded microemulsion for intranasal delivery and evaluation of the targeting efficiency to brain. Int J Pharm 275:85-96.